Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cryo Cell International (CCEL) Other Operating Expenses (2016 - 2026)

Cryo Cell International's Other Operating Expenses history spans 17 years, with the latest figure at $1.8 million for Q1 2026.

  • Quarterly results put Other Operating Expenses at $1.8 million for Q1 2026, down 15.44% from a year ago — trailing twelve months through Feb 2026 was $12.2 million (up 39.31% YoY), and the annual figure for FY2025 was $11.6 million, up 34.1%.
  • Other Operating Expenses for Q1 2026 was $1.8 million at Cryo Cell International, down from $6.3 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $18.2 million in Q4 2023 to a low of $1.8 million in Q4 2024.
  • The 5-year median for Other Operating Expenses is $2.3 million (2024), against an average of $3.4 million.
  • The sharpest move saw Other Operating Expenses skyrocketed 600.25% in 2023, then tumbled 89.91% in 2024.
  • Year by year, Other Operating Expenses stood at $2.6 million in 2022, then skyrocketed by 600.25% to $18.2 million in 2023, then tumbled by 89.91% to $1.8 million in 2024, then surged by 242.49% to $6.3 million in 2025, then tumbled by 70.68% to $1.8 million in 2026.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $1.8 million, $6.3 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.